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Abstract
Background. Neuropsychological investigations can help untangle the aetiological and phe-
nomenological heterogeneity of schizophrenia but have scarcely been employed in the context
of treatment-resistant (TR) schizophrenia. No population-based study has examined neuro-
psychological function in the first-episode of TR psychosis.
Methods. We report baseline neuropsychological findings from a longitudinal, population-
based study of first-episode psychosis, which followed up cases from index admission to 10
years. At the 10-year follow up patients were classified as treatment responsive or TR after
reconstructing their entire case histories. Of 145 cases with neuropsychological data at base-
line, 113 were classified as treatment responsive, and 32 as TR at the 10-year follow-up.
Results. Compared with 257 community controls, both case groups showed baseline deficits
in three composite neuropsychological scores, derived from principal component analysis: ver-
bal intelligence and fluency, visuospatial ability and executive function, and verbal memory and
learning ( p values⩽0.001). Compared with treatment responders, TR cases showed deficits in
verbal intelligence and fluency, both in the extended psychosis sample (t =−2.32; p = 0.022)
and in the schizophrenia diagnostic subgroup (t =−2.49; p = 0.017). Similar relative deficits in
the TR cases emerged in sub-/sensitivity analyses excluding patients with delayed-onset treatment
resistance ( p values<0.01–0.001) and those born outside the UK ( p values<0.05).
Conclusions. Verbal intelligence and fluency are impaired in patients with TR psychosis com-
pared with those who respond to treatment. This differential is already detectable – at a group
level – at the first illness episode, supporting the conceptualisation of TR psychosis as a severe,
pathogenically distinct variant, embedded in aberrant neurodevelopmental processes.
Introduction
Schizophrenia and other psychoses are severe neuropsychiatric disorders, heterogeneous in
aetiology, clinical trajectory and treatment response (Fanous and Kendler, 2005; van Os,
2016). In approximately 30% of schizophrenia patients, psychotic symptoms respond poorly,
if at all, to most antipsychotics, with the notable exception of clozapine (Elkis and Buckley,
2016; Gillespie et al., 2017; Howes et al., 2017). This emerged as the gold-standard pharma-
cological intervention for ‘treatment-resistant schizophrenia’ (TRS) in 1988 (Kane et al.,
1988). Since then, studies have varied considerably in their definitions of TRS (Howes
et al., 2017), although there is a consistent minimum requirement of two periods of adherence
to two different antipsychotics, each administered at adequate doses (variously defined) for at
least 4 weeks, resulting in symptom reductions of <20% (Gillespie et al., 2017).
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Recent evidence suggests that TRS is neurobiologically and cat-
egorically distinct from treatment-responsive schizophrenia
(Gillespie et al., 2017). Unlike treatment-responsive patients,
treatment-resistant (TR) ones do not exhibit an elevation in dopa-
mine synthesis capacity (Demjaha et al., 2012), and instead, show
elevated glutamate levels in the anterior cingulate cortex
(Demjaha et al., 2014). In addition, previous findings from the
ÆSOP-10 study (Aetiology and Ethnicity in Schizophrenia and
Other Psychoses) by our group showed that 84% of TR patients
were resistant from illness onset (primary TRS), while the
remaining 16% made an initial response to antipsychotics, but
became TR later (secondary TRS) (Demjaha et al., 2017). Lally
et al. (2016) showed similar results in the GAP (Genetics and
Psychosis) first-episode study, with 70% of TR patients having
primary TRS.
Despite emerging evidence that specific combinations of cog-
nitive deficits define disease heterogeneity as related to treatment
response (Gilbert et al., 2014), neuropsychological investigations
largely remain an untapped resource for characterising the origin
and mechanism of TRS. To date, only six studies have compared
neuropsychological function between TR and treatment-
responsive patients with psychosis, showing the former to have
consistent relative deficits in verbal domains, such as language,
verbal intelligence, verbal memory, verbal fluency and verbal
interference (Joober et al., 2002; de Bartolomeis et al., 2013;
Iasevoli et al., 2016), less consistently reported deficits in non-
verbal domains, such as performance intelligence, processing
speed, visuospatial function and visual memory (Joober et al.,
2002; Bourque et al., 2013; Frydecka et al., 2016), and no cogni-
tive differences from treatment-responsive patients in one study
(Anderson et al., 2015).
All the above studies have involved cross-sectional investiga-
tions of chronically ill samples with schizophrenia or schizoaffect-
ive disorder, and with established group differences in treatment
response and medication profiles. The respective research designs
and methodologies have allowed limited conclusions with regard
to two important questions: (1) Do neuropsychological differ-
ences between TR and treatment-responsive individuals reflect
premorbid differences or the impact of non-remitting psychosis?
(2) Do findings from TRS generalise to other psychoses?
To address these questions, we examined baseline neuro-
psychological data from ÆSOP-10, a population-based study of
first-episode psychosis (FEP) with a 10-year follow-up (Fearon
et al., 2006; Morgan et al., 2006, 2014). All neuropsychological
assessments were carried out during the patients’ first episode
of psychosis, approximately 10 years before participants were
characterised as TR or treatment responsive following detailed
re-constructions of their case histories by the ÆSOP team
(Demjaha et al., 2017). In line with the TRS literature and with
additional neuropsychological findings in support of dimensional
models of psychosis (Kravariti et al., 2012), we predicted that TR
patients would show deficits in verbal tasks of intelligence, fluency
and memory compared with treatment-responsive patients and
community controls, both among participants with schizophrenia
and in the extended sample with various psychoses.
Methods
The ÆSOP-10 study
The present analysis included baseline neuropsychological, socio-
demographic and clinical data from ÆSOP-10 (Aetiology and
Ethnicity in Schizophrenia and Other Psychoses), a 10-year lon-
gitudinal follow-up, population-based study of FEP (Fearon
et al., 2006; Morgan et al., 2006). The study identified all indivi-
duals aged 16–65 years with FEP [codes F20–F29 and F30–F33 in
the International Classification of Diseases, 10th Revision
(ICD-10) manual (World Health Organisation: WHO, 1992a)],
who presented to specialist mental health services in tightly
defined catchment areas in Southeast London, Nottingham and
Bristol between September 1997 and August 2000. Exclusion cri-
teria were the previous contact with health services for psychosis,
organic causes of psychotic symptoms, transient psychosis due to
acute intoxication (as defined by ICD–10) and IQ<50. [Due to the
primary focus of this analysis on neuropsychological functions,
we used a higher threshold of inclusion herein: IQ>69, as assessed
by the Wechsler Intelligence Scale-Revised (WAIS-R; Wechsler,
1981)]. The study further included a random sample of commu-
nity controls with no past or present psychotic disorder, recruited
using mainly a sampling method that matched cases and controls
by area of residence. Across the three centres, 568 cases with con-
sensus diagnoses of psychotic illness who met the study inclusion
criteria, and 412 community controls, were identified. Patients
provided detailed contact information for themselves, their
General Practitioners (GPs) and relatives, and consent to be re-
contacted for follow-up. Ethical approvals for the baseline and
follow-up studies were obtained from local research ethics com-
mittees. Detailed overviews of the ÆSOP study design and proce-
dures have been published elsewhere (Fearon et al., 2006; Morgan
et al., 2006, 2014; Demjaha et al., 2017).
Baseline assessment of sociodemographic and clinical
characteristics
Sociodemographic data were collected by interviews with the par-
ticipants using the Medical Research Council Sociodemographic
Schedule (Mallett, 1997). Information gaps were filled using add-
itional data sources, including case notes and other informants.
Clinical data were collected as soon as possible after the first con-
tact with psychiatric services using the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN; WHO, 1992b). The
SCAN incorporates the Present State Examination (PSE) –
Version 10, which was used to elicit symptom-related data at pres-
entation. Where a patient interview was not possible, case notes
and, when available, information from informants, were used to
complete the SCAN Item Group Checklist. Baseline symptom
scores were further subjected to factor analysis, giving rise to
five psychopathological dimensions: manic, reality distortion,
negative, depressive and disorganization symptom dimensions
(for full details, see Demjaha et al., 2009). Patients’ ICD–10 diag-
noses were determined using the SCAN data on the basis of con-
sensus meetings involving a principal investigator (PI) and other
members of the research team with satisfactory interrater reliabil-
ity (κ values ranged from 0.63 to 0.75, p < 0.001). Duration of
untreated psychosis (DUP) was defined as the period from the
onset of psychosis to the first contact with statutory mental health
services (for full details, see Morgan et al., 2006). Data on illicit
substance use before the first presentation to mental health ser-
vices were collected retrospectively using an ad hoc secondary
data collection schedule, which collated data on prevalence and
type of illicit substance use from relatives or carers, from the
SCAN (WHO, 1992b) and from clinical case notes. Controls
were screened for psychosis using the Psychosis Screening
Questionnaire (Bebbington and Nayani, 1995). Those with a
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positive rating were further assessed using the SCAN (WHO,
1992b) and, where appropriate, excluded.
Baseline neuropsychological assessment
The present analysis included neuropsychological data collected at
baseline using the National Adult Reading Test-Revised (NART-
R) (Nelson and Willison, 1991), assessing premorbid intelligence;
the Vocabulary, Comprehension, Block Design, and Digit Symbol
subtests of the WAIS-R (Wechsler, 1981), assessing verbal and
non-verbal intelligence; trials 1–5 and 7 of the Rey Auditory
Verbal Learning Test (RAVLT) (Spreen and Strauss, 1991), asses-
sing immediate and delayed verbal recall and learning; the imme-
diate Visual Reproduction trials of the Wechsler Memory Scale –
Revised (WMS-R) (Wechsler, 1987), assessing visual memory; the
Trail Making A (Reitan, 1958), Trail Making B (Reitan, 1958) and
Letter-Number Span (Gold et al., 1997) tests of processing speed,
working memory and executive function; and Category and Letter
Verbal Fluency (category: ‘body parts’, ‘fruits’ and ‘animals’; let-
ter: F, A, S), assessing verbal ability and executive control.
Follow-up clinical assessment
At approximately 10 years after inclusion, we made an attempt to
trace, re-contact and re-assess 557 ÆSOP participants with psych-
osis, who had initially been identified in the Southeast London
and Nottingham centres. Using an extended version of the
WHO Life Chart Schedule (LCS) (WHO, 1992c) and a
Medication History Timeline, comprehensive information on psy-
chopathology, all prescribed antipsychotic medications (start and
end date, dosage, adherence, reasons for change or termination),
substance use and contact with mental health services was col-
lected and rated for the entire follow-up period using a wide
range of information sources: medical case records, follow-up
interview with participant or informants (where possible), treat-
ing clinicians, ward and community prescriptions, medication
charts and clinical documentation (including, where available,
reports of drug level testing, and correspondence from the pre-
scribing clinician/to GPs). Using the above sources, adherence
to each prescribed antipsychotic throughout the period it was pre-
scribed was rated on a three-point scale (1: 0–33%; 2: 34–67%; 3:
68–100%), using 68% as the cut-off for ‘adherence’. Presence of
symptoms at follow-up was further assessed using the Scan –
Version 2 (WHO, 1994). Based on all available information,
case histories were reconstructed for the entire follow-up period
to complete all sections of the Life Chart. A detailed overview
of the follow-up clinical assessment procedures has been pub-
lished elsewhere (Morgan et al., 2014; Demjaha et al., 2017).
Representativeness of the follow-up sample
Of the 557 cases who were initially recruited, 434 (78%) under-
went follow-up assessments. There were no marked differences
in gender, ethnicity, duration of untreated psychosis, or diagnosis
between the cases who underwent follow-up assessments and
those who were lost to follow-up, except that the follow-up sample
was younger (t = 2.5; p = 0.02).
Criteria for treatment response and treatment resistance
‘Response to treatment’ was defined as a state of no or mild symp-
toms (SCAN score<2), not interfering with daily functioning,
lasting at least 6 months (Andreasen et al., 2005). In line with
National Institute for Health and Care Excellence (NICE) criteria
(National Institute for Health and Care Excellence, 2014), patients
were classified as ‘Treatment Resistant’, if, despite recorded adher-
ence to medication, they continued to show positive symptoms of
at least moderate severity (SCAN score⩾2) following two sequen-
tial trials of antipsychotic medication at a daily dose of 400–
600 mg of chlorpromazine equivalence, each lasting at least 4
weeks. Patients were classified as ‘Treatment Resistant from
Illness Onset’ (TRO) if they met resistance criteria after the first
two trials of antipsychotic medication, and as ‘Delayed Onset
Treatment Resistant’ (DOTR), if such criteria were met after a
period of response to treatment. An individual meeting treatment
resistance criteria, but later meeting treatment response criteria,
would have been classified as treatment resistant. However, the
ÆSOP-10 Study did not identify individuals whose response to
medication improved during the course of illness. Of the 50
patients who received clozapine (by definition TR), 14 (28%)
were clozapine responders, 12 (24%) were clozapine resistant,
and the remaining 24 (48%) could not be classified, due to a sub-
optimal clozapine trial or insufficient clinical and response data
(Demjaha et al., 2017).
Representativeness of the follow-up sample that was
evaluated for treatment response
Of the 434 cases who were assessed at follow-up, 212 (49%) met
criteria for treatment response, 74 (17%) met criteria for treat-
ment resistance (of whom 62: 84% were TRO) and 37 (9%) had
never received an adequate trial of antipsychotic medication
and could not be included in either category. The remaining
111 participants (26%) had incomplete clinical information docu-
mentation and could not be classified. Cases with complete infor-
mation did not differ notably from the remainder of the follow-up
sample in terms of age, gender, ethnicity, DUP or diagnosis
(Demjaha et al., 2017).
Statistical analysis
Data reduction and generation of composite neuropsychological
scores
To avoid the caveats of multiple testing and of experimenter
assumptions during the grouping of cognitive tasks into overarch-
ing constructs (e.g. executive function), we reduced an original set
of 13 neuropsychological variables to a small number of compo-
nents, using Principal Component Analysis (PCA) with promac
oblique rotation in Stata/MP 14.0 (StataCorp, 2015). This was
performed on the present analytic cohort, i.e. 402 ÆSOP partici-
pants (145 cases, 257 controls) with available neuropsychological
data at baseline (all participants), and with entire case history
reconstruction at the 10-year follow-up (cases only). Where
appropriate, variables were inverse transformed to achieve
normality of distribution. The selected cut-off for the variable
loadings on the PCA components was 0.30, in line with recom-
mendations that this has practical significance for sample sizes
of at least 350 (Hair et al., 1998, p. 112). The oblique method
was preferred over the varimax solution for its superior capacity
to identify a simple factorial structure, particularly in datasets
where the latent traits are correlated (Finch, 2006). The Kaiser-
Meyer-Olkin (KMO) test of sampling adequacy was used to
determine the factorability of the data. To generate composite
neuropsychological scores (each reflecting a participant’s
Psychological Medicine 3
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composite ability across variables with primary loadings on a cer-
tain component), we estimated PCA scores using Stata’s predict
command with the score option immediately after the PCA com-
mand. The PCA scores are expressed in standardised units based
on linear combinations of the retained components.
Comparison of composite neuropsychological scores across
study groups
Statistical analysis was performed in Stata/MP 14.0 (StataCorp,
2015). Each of the main and sensitivity (see below) analyses was a
multivariable regression analysis with robust standard errors, com-
paring selected study groups or subgroups in each composite neuro-
psychological score. All main and sensitivity analyses co-varied for
sociodemographic and (where appropriate) clinical variables that
were associated with each composite score at p < 0.1 in preliminary
univariable linear regression analyses (see online Supplementary
Table S1). Composite neuropsychological scores were compared
across the TR, treatment-responder (non-TR) and community con-
trol groups, as well as between TR and non-TR cases in the full
patient sample and in the diagnostic subgroup with schizophrenia.
Performing separate analyses for cases who were TR from Illness
Onset (TRO) and those who had Delayed-Onset Treatment
Resistance (DOTR) would enhance the interpretability of our find-
ings. However, this was not possible due to the small size of the
DOTR subgroup (n = 6). We instead repeated all data analytic
steps in sub-analyses which excluded the DOTR patients.
Sensitivity analysis
All main statistical analyses uniformly controlled for the effects of
ethnicity and education. However, as the TR group had a higher
proportion of Black ethnic minorities (47%) than the non-TR
(24%) and control (14%) groups (see Results and Table 1), it was
important to further address potential confounding influences of
language in our analysis. We, therefore, assessed the sensitivity of
our findings to excluding all participants who had been born out-
side the UK, regardless of ethnicity or first language (n = 58; 15
non-TR, 6 TR, 37 controls). This left in the analysis an all-UK-
born sample who had attended compulsory schooling in the UK.
Missing data
The level of completeness of sociodemographic and clinical infor-
mation at the time of the baseline neuropsychological assessment
was high (96–100% for socio-demographic variables and 82–
100% for clinical variables). The high level of completeness at
baseline is partly attributable to the temporal proximity of the
sociodemographic, clinical and neuropsychological assessments,
which were typically completed within a few days of each other.
Antipsychotic medication history was re-constructed in detail at
the 10-year follow up. Exact recording of neuropsychological test-
ing dates at baseline was available only in a subset of cases, allow-
ing us to map the participants’ complex medication histories onto
the dates of their neuropsychological testing in a subgroup of 75
cases (52%, 57 non-TR, 18 TR). Detailed information on the
medication received by this subgroup is presented in online
Supplementary Table S2.
Results
Representativeness of the analytic cohort
Of the 286 cases who were classified in terms of treatment
response at follow-up (see Methods), 136 cases (48%) lacked
neuropsychological data at baseline, and 5 (2%) had IQ<70, leav-
ing 113 non-TR cases, 32 TR cases (of whom 26: 81% were TRO),
and 257 community controls in the present analysis. There were
no notable differences in age, gender, DUP or diagnosis between
the patient analytic cohort (n = 145), and those who lacked neuro-
psychological data at baseline or met exclusion criteria (N = 141).
However, the patient analytic cohort (treatment-responders and
TR cases combined) comprised a lower proportion of black ethnic
minorities (29%) than the cases who lacked neuropsychological
data or who met exclusion criteria (51%; χ2 = 14.563, p = 0.001).
Sociodemographic and clinical characteristics
The sociodemographic and clinical characteristics of the analytic
cohort are presented in Table 1. Compared with controls, both
patient groups were younger, had fewer years of education, and
a higher proportion of male and Black participants ( p < 0.01–
0.0001). Compared with treatment-responders, TR cases were
younger, had a higher proportion of male and Black participants,
a higher score on the negative symptom dimension, and a longer
duration of untreated psychosis ( p < 0.05–0.0001) (Table 1). The
two patient groups did not differ statistically significantly in illicit
substance use [positive lifetime history present in 27 (25%)
non-TR- and in 4 (12.5%) TR participants; χ2 = 2.237, p = 0.135].
Data reduction and estimation of composite
neuropsychological scores
The PCA gave rise to a three-component solution (eigenvalues
1.20–5.78) accounting for 0.65% of the variance. The results of
the promax rotation of the solution are presented in Table 2.
NART IQ, WAIS-R Vocabulary, WAIS-R Comprehension,
Phonological Verbal Fluency and Semantic Verbal Fluency
showed primary loadings (0.306–0.520) on Component 1,
which was labelled Verbal Intelligence and Fluency. WAIS-R
Block Design, WAIS-R Digit Symbol and Trail Making (A & B)
showed primary loadings (0.332–0.565) on Component 2,
which was labelled Visuospatial Ability and Executive Function.
The immediate and delayed recall trials of the RAVLT showed pri-
mary loadings (0.598–0.698) on Component 3, which was labelled
Verbal Memory and Learning. The Kaiser-Meyer Olkin measure
of sampling adequacy indicated that the sample had very high fac-
torability (KMO = 0.875). Composite neuropsychological scores
(PCA scores) were generated for the three components and
used in the remaining analyses.
Comparison of composite neuropsychological scores across
study groups
Tables 3 and 4 present the means and standard deviations of the
composite neuropsychological scores in the three study groups, as
well as the results and effect sizes of selected group comparisons.
Figure 1 presents the distribution of the composite scores in
Verbal Intelligence and Fluency in the full analytic cohort divided
by study group. Both patient samples were impaired in all com-
posite scores compared with controls ( p⩽0.001) (Table 3), with
moderate to large effect sizes in the treatment-responsive patients
and with large to very large effect sizes in the TR cohort.
Compared to non-TR patients, the TR cases performed worse
in Verbal Intelligence and Fluency in all main analyses ( p < 0.05)
(Tables 3 and 4; Figure 1), sub-analyses ( p < 0.01–0.001) (exclud-
ing DOTR case: online Supplementary Tables S3 and S4), and
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sensitivity analyses ( p < 0.05) (excluding non-UK-born partici-
pants: online Supplementary Tables S5 and S6).
In the schizophrenia subgroup, TR cases performed worse
than non-TR patients in Visuospatial Ability and Executive
Function ( p < 0.05) (Table 4), but the finding did not persist in
our sub-analyses or sensitivity analyses (online Supplementary
Tables S3–S6).
Discussion
Summary of findings
Our analysis of baseline data from the ÆSOP-10 longitudinal,
population-based study of FEP provides a snapshot of the neuro-
psychological function at the earliest stages of TR psychosis. Both
TR and treatment-responsive patients with schizophrenia and
Table 1. Sociodemographic and clinical characteristics in the treatment-responder, treatment-resistant and community control groups
Treatment-responder
(n = 113)
Treatment-resistant
(n = 32)
Community control
(n = 257)
Mean S.D. Mean S.D. Mean S.D. F p Value
Education (years)a 12.60 2.36 12.10 1.90 13.26 2.55 5.97 0.003
Age at Assessment (years)b 30.75 10.60 26.63 9.07 39.73 13.16 62.81 <0.0001
Age at Illness Onset (years) 30.23 10.67 25.41 9.02 – – 5.71 0.018
Days of Untreated Psychosis 197.58 528.52 633.04 1097.00 – – 4.81 0.030
Antipsychotic Defined Daily Dose (DDD)c 334.66 238.56 427.81 229.71 – – 1.89 0.174
Reality Distortion 3.41 2.55 4.00 3.24 – – 0.70 0.405
Disorganisation 0.69 0.96 0.83 0.82 – – 0.52 0.471
Negative Symptoms 1.21 1.76 2.38 2.62 – – 4.36 0.039
Mania 1.94 2.73 1.63 2.32 – – 0.33 0.568
Depression 1.43 1.85 1.09 1.84 – – 0.70 0.405
N % N % N % Pearson χ2 p Value
Gender:d 17.39 <0.0001
Male 63 55.8 25 78.1 109 42.4
Female 50 44.2 7 21.9 148 57.6
Ethnicity: e,
f
Fisher’s f <0.001
White 72 63.7 13 40.6 211 82.1
Black 27 23.9 15 46.9 37 14.4
Other 14 12.4 4 12.5 9 3.5
Level of Completed Education:g 7.604 0.107
School 65 63.1 19 67.9 131 51.4
Further 19 18.4 7 25.0 69 27.1
Higher 19 18.4 2 7.1 55 21.6
Diagnosis:f Fisher’sf 0.004
Schizophrenia 43 38.1 24 75.0 – –
Bipolar Disorder or Mania 24 21.2 2 6.3 – –
Depressive Psychosis 18 15.9 2 6.3 – –
Other Psychotic Disorder 28 24.8 4 12.5 – –
Antipsychotic Type c,
f
Fisher’s f 0.725
Typical 22 38.6 8 44.4 – –
Atypical 33 57.9 9 50.0 – –
Combination of Typical & Atypical 2 3.5 1 5.6 – –
Bold denote significance level for p values.
aTR, non-TR<CC.
bTR, non-TR<CC, TR<non-TR.
cData was available for a subset of 75 cases (52%).
dProportion Male: TR, non-TR>CC; TR>non-TR.
eProportion Black: TR, non-TR>CC; TR>non-TR.
fAs the statistical assumptions for the χ2 test were violated, Fisher’s Exact Test was performed.
gLevel of completed education was missing for 16 participants (4%).
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other psychoses showed generalised neuropsychological deficits in
verbal intelligence and fluency, visuospatial abilities and executive
function, and verbal memory and learning compared with com-
munity controls. Furthermore, TR patients showed, on average,
impairments in verbal intelligence and fluency compared with
treatment responders, replicating previous findings (Joober
et al., 2002; Frydecka et al., 2016). This differential was an endur-
ing finding of our analyses – evident for individuals with schizo-
phrenia, those with any psychoses, psychotic and schizophrenia
patients born in the UK, and after excluding cases with
delayed-onset treatment resistance.
Methodological considerations
This is the first longitudinal, population-based study of FEP that
compared baseline neuropsychological function across patients
with longitudinally-defined TR- and non-TR psychosis and com-
munity controls. The study draws on unique methodological
advantages: The epidemiological source and robust size of the
combined patient and community control groups increased the
representativeness of our cohort and generalisability of our find-
ings, whilst facilitating stringent statistical controls (including a
sensitivity analysis) for a wide array of clinical, sociodemographic,
and language confounders. Analysing neuropsychological data
from the first episode minimised information bias (i.e. examiners
did not know the participants’ treatment response status at the
time of testing) and reduced differentiation in clinical features
between the two patient groups. Specifically, in contrast to all pre-
vious neuropsychological studies of TRS (Joober et al., 2002;
Bourque et al., 2013; de Bartolomeis et al., 2013; Anderson
et al., 2015; Frydecka et al., 2016; Iasevoli et al., 2016), our patient
groups did not seem to differ notably in treatment profiles or
medication doses at the time of testing (based on a subgroup ana-
lysis). These aspects served to further reduce confounding in our
analysis.
Methodological limitations of our study include loss to follow
up; limitations on clinical data accuracy associated with case his-
tory reconstruction; the availability of baseline neuropsychological
testing dates for only a subgroup of patients; the lack of screening
for family history of psychosis in community controls; and the
moderate size of the TR cohort. A deficit in verbal intelligence
and fluency in TR patients compared with responders was a
highly consistent finding across our main analyses, sub-analyses
and sensitivity analyses. However, we cannot exclude the possibil-
ity that additional deficits are integral to TR psychosis, particu-
larly in relation to schizophrenia (discussed below). Our
selected cut-off for factor loadings (0.30) is among the lowest
reported in the literature (Peres-Neto et al., 2003), and may
have reduced the clarity of the PCA components. Using a 0.40
cut-off would not have changed the pattern of findings (data
available upon request). Finally, our analyses included baseline
diagnoses. As with the extended ÆSOP sample (Heslin et al.,
2015), most schizophrenia patients (77%) and 40% of those
with ‘other’ diagnoses in our analytic cohort were classified as
having schizophrenia at 10 years. Using diagnostic classifications
at follow up, 31.5% of schizophrenia patients would have been
classified as TR compared with 35.8% using baseline diagnoses.
TR psychosis as a severe neurodevelopmental variant of
psychosis
The neurodevelopmental theory of schizophrenia posits the exist-
ence of a neurodevelopmental subtype of schizophrenia, which is
the end product of aberrant neurodevelopmental processes
unfolding from conception or early life (Murray et al., 1992). It
has been suggested that primary TRS has a distinct neurodevelop-
mental origin, while secondary TRS may arise through the induc-
tion of dopamine super-sensitivity, or after periods of relapse,
although a later emergence of an intrinsic treatment resistance,
or a combination of underlying factors cannot be ruled out
(Lally et al., 2016; Demjaha et al., 2017; Gillespie et al., 2017).
The clinical and demographic profiles of the TR cases in the pre-
sent study largely encapsulate the defining features of ‘neurodeve-
lopmental schizophrenia’ – younger, ‘more male’, with an earlier
age of onset, more severe negative symptoms, more severe cogni-
tive impairment and a longer duration of untreated psychosis
(Murray et al., 1992). Three further observations suggest a patho-
genic origin for the observed verbal deficit in the TR group com-
pared with treatment-responsive individuals. Firstly, the
impairment was established by the first episode, arguing against
the deficit being caused by non-remitting psychosis. Secondly,
Vocabulary and NART-R, two tasks with primary loadings on
Verbal Intelligence and Fluency, are reliable tests of premorbid
ability, and are both resistant to brain pathological changes
(Bright et al., 2002; de Oliveira et al., 2014). Finally, the pattern
of deficits in verbal intelligence and fluency was accentuated (def-
icits were significant at a lower level of statistical significance)
after removing cases with secondary treatment resistance.
Black participants were over-represented among TR patients.
Although Black ethnicity is not a defining feature of ‘neurodeve-
lopmental schizophrenia’ (Murray et al., 1992), the finding is in
keeping with evidence that treatment resistance is associated
Table 2. Obliquely rotated component loadingsa for 13 neuropsychological
variables in the analytic cohortb (n = 402)
Component loadings
1 2 3
WAIS-R vocabulary 0.520 0.103 0.025
WAIS-R comprehension 0.487 0.124 0.067
NART-R IQ 0.485 0.045 −0.017
Phonological verbal fluency (Letter) 0.322 −0.122 −0.169
Semantic verbal fluency (Category) 0.306 −0.178 −0.119
Trail making A 0.113 0.565 0.113
Trail making B 0.064 0.505 0.030
WAIS-R digit symbol 0.027 0.416 0.016
WAIS-R block design 0.019 0.332 0.133
RAVLT trials 1–5 0.090 0.046 0.598
RAVLT trial 7 −0.047 0.052 0.698
WMS-R visual reproduction (Total score) −0.052 −0.254 0.236
Letter-number span 0.203 −0.126 0.155
NART-R, National Adult Reading Test-Revised; RAVLT, Rey Auditory Verbal Learning Test;
WAIS-R, Wechsler Adult Intelligence Scale-Revised.
aVariables with primary loadings of >0.30 are set against a grey background, and high
loadings of >0.50 are highlighted in bold font.
bThe sample included participants who had undergone neuropsychological testing at
baseline, had IQ ⩾70, and could be classified (in the case of patients, retrospectively, i.e. at
the 10-year follow-up) as treatment responders (n = 113), treatment-resistant (n = 32), or
community controls (n = 257).
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Table 3. Comparisona of composite neuropsychological scores across the treatment-responder, treatment-resistant and community control groups
Responder
(n = 113)
Treatment-resistant
(n = 32)
Community
control
(n = 257) Regression modela
Mean S.D. Mean S.D. Mean S.D. F(D.F.) p Value
Verbal intelligence & fluency −0.81 1.81 −1.91 1.68 0.59 1.64 40.15(7, 386) <0.0001
Visuospatial ability & executive function −0.71 1.79 −1.29 2.00 0.47 1.66 37.12(7, 387) <0.0001
Verbal memory & learning −0.37 1.29 −1.13 1.43 0.30 1.37 21.99(7, 386) <0.0001
Post-Hoc comparisonsa
Cohen’s db Cohen’s dc
Responder
v. Control
Treatment-Resistant
v. Control
Responder
v. Treatment-Resistant
d 95% CI d 95% CI t p Value t p Value t p Value
Verbal intelligence & fluency −0.83 −1.06 to −0.60 −1.52 −1.91 to −1.13 −4.12 <0.001 −5.22 <0.001 2.35 0.019
Visuospatial ability & executive function −0.69 −0.92 to −0.47 −1.04 −1.41 to −0.66 −6.60 <0.001 −5.32 <0.001 1.44 0.150
Verbal memory & learning −0.50 −0.72 to −0.27 −1.04 −1.42 to −0.66 −4.36 <0.001 −4.38 <0.001 1.94 0.053
Bold denote significance level for p values.
aThe effect of Group (Treatment Responder, Treatment-Resistant, Community Control) on each Composite Score was examined using multivariable regression analysis with robust standard errors, co-varying for demographic variables that emerged as
significant ( p < 0.05) or suggestive ( p < 0.1) predictors of each Composite Score in preliminary univariable linear regression analyses (online Supplementary Table S1): Age, Ethnicity, Years of Education (all Composite Scores) and Gender (Verbal
Intelligence & Fluency; Verbal Memory & Learning).
bStandardised mean difference the between treatment-responder and community-control groups.
cStandardised mean difference between the treatment-resistant and community-control groups.
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Table 4. Comparison of composite neuropsychological scores between the treatment-responder and treatment-resistant groups
Independent effect of group (Responder v. Treatment-resistant)
Coefficient Stand. Err. 95% CI t p Value
All diagnoses
Verbal intelligence & fluencya −0.76 0.32 −1.40 −0.12 −2.35 0.020
Visuospatial ability & executive functionb −0.70 0.57 −1.84 0.45 −1.23 0.226
Verbal memory & learningc −0.40 0.52 −1.46 0.66 −0.76 0.453
Schizophrenia
Verbal intelligence & fluencya −0.96 0.38 −1.72 −0.20 −2.56 0.014
Visuospatial ability & executive functionb −1.55 0.61 −1.95 0.28 −2.55 0.019
Verbal memory & learningc −0.35 0.74 −1.90 1.20 −0.48 0.640
Bold denote significance level for p values.
aThe effect of Group (Treatment Responder v. Treatment Resistant) on Verbal Intelligence & Fluency was examined using multivariable regression analysis with robust standard errors,
co-varying for demographic and clinical variables that emerged as significant ( p < 0.05) or suggestive ( p < 0.1) predictors of Verbal Intelligence & Fluency in preliminary univariable linear
regression analyses (online Supplementary Table S1): Age, Gender, Ethnicity, Years of Education, Negative Symptoms, Mania and Depression. The analysis for ‘All Diagnoses’ additionally
co-varied for ‘Diagnosis’.
bThe effect of Group (Treatment Responder v. Treatment Resistant) on Visuospatial Ability & Executive Function was examined using multivariable regression analysis with robust standard
errors, co-varying for demographic and clinical variables that emerged as significant ( p < 0.05) or suggestive ( p < 0.1) predictors of Visuospatial Ability & Executive Function in preliminary
univariable linear regression analyses (online Supplementary Table S1): Age, Ethnicity, Years of Education, Age at Illness Onset, Negative Symptoms, Mania, Medication Dose (expressed in
Defined Daily Dose units) and Illicit Substance Use [positive/negative lifetime history of, based on information collected from relatives or carers, the Schedules for Clinical Assessment in
Neuropsychiatry (SCAN; WHO, 1992b), clinical case notes and an extended version of the WHO Life Chart Schedule (WHO, 1992c)]. The analysis for ‘All Diagnoses’ additionally co-varied for
‘Diagnosis’.
cThe effect of Group (Treatment Responder v. Treatment Resistant) on Verbal Memory & Learning was examined using multivariable regression analysis with robust standard errors, co-varying
for demographic and clinical variables that emerged as significant ( p < 0.05) or suggestive ( p < 0.1) predictors of Verbal Memory & Learning in preliminary univariable linear regression
analyses (online Supplementary Table S1): Age, Gender, Ethnicity, Years of Education, Duration of Untreated Psychosis, Reality Distortion, Negative Symptoms, Mania and Medication Dose
(expressed in Defined Daily Dose units). The analysis for ‘All Diagnoses’ additionally co-varied for ‘Diagnosis’.
Fig. 1. Distribution of Composite Verbal Intelligence & Fluency Scores in the Complete Analytic Cohorts of Treatment-Resistant, Treatment-Responder and
Community Control Participants.
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with early first contact with psychiatric services (<20 years), and
more so in Black (OR 3.71) than in White (OR 1.60) patients
(Lally et al., 2016). Indeed, a closer look at our data revealed
that only 9.4% of White patients, but 21.4% of Black patients
had the first contact with psychiatric services before age 20,
which may have increased disproportionately the outcome of
treatment resistance in the Black ethnic group.
TR schizophrenia
An additional deficit in visuospatial ability and executive function
emerged in TR- compared with non-TR patients in the schizo-
phrenia subgroup. This finding did not generalise to the ‘all-
diagnoses’ group and did not persist in our sub-analyses or
sensitivity analyses. The finding is consistent with evidence that
deficits in executive function, processing speed and verbal mem-
ory, albeit less salient in other diagnostic categories of psychosis,
are prototypical of schizophrenia (Kravariti et al., 2009a, 2009b;
Zanelli et al., 2010). As the size of the schizophrenia subgroup
in the present study was modest, it is important to explore the sig-
nificance of executive function and verbal memory deficits in TR
schizophrenia in larger studies.
Integrating neurodevelopmental and glutamatergic
hypotheses of TR psychosis
Some recent findings implicate glutamate rather than dopamine
as the primary neurotransmitter system impaired in TR schizo-
phrenia (Demjaha et al., 2012, 2014; Gillespie et al., 2017).
Glutamate plays an important role in several language-related
neurodevelopmental processes. This highlights the possibility
that core deficits in verbal intelligence and fluency, a neurodeve-
lopmental aetiology, and a primary glutamatergic dysfunction
may converge in a single model of TR psychosis. Several lines
of evidence support this possibility: pre-reading language abilities
(e.g. phonological processing) show significant correlations with
glutamate in the anterior cingulate of healthy preschool-aged chil-
dren (Lebel et al., 2016); microdeletions in glutamate receptors
have been implicated in developmental delays predominantly
affecting language and fine motor skills (Takenouchi et al.,
2014); the high-risk metabotropic glutamate receptor 3 (GRM3)
haplotype is associated with schizophrenia, as well as with deficits
in verbal fluency and verbal list-learning (Spangaro et al., 2012);
and poor-functioning subjects at ultra-high-risk for psychosis
show a negative relationship between thalamic glutamate levels
and prefrontal-striatal activation during a verbal fluency task
(Allen et al., 2015).
Clinical and research implications
Neuropsychological deficits weigh disproportionally on the psy-
chosocial and functional toll of psychosis (Kaneda et al., 2010;
Shamsi et al., 2011; Iasevoli et al., 2016). Encouragingly, verbal
fluency and executive function deficits, which differentiated TR
from non-TR patients in the present study, do not seem refractory
to pharmacological interventions. Indeed, there is strong evidence
that clozapine improves attention and verbal fluency, and moder-
ate evidence that it improves some types of executive function
(Meltzer and McGurk, 1999; Woodward et al., 2005). In the
only studies to report equivalent verbal performances in TRS-
and non-TRS patients to date, TR cases were uniformly treated
with clozapine (Bourque et al., 2013; Anderson et al., 2015).
These findings re-iterate the necessity of timely detection and tai-
lored pharmacological interventions as early as possible in the
course of TR psychosis (Lally and MacCabe, 2016). They further
highlight the importance of neuropsychological constructs in
designing multimodal research and clinical approaches to improv-
ing prognosis and personalised treatment (Gilbert et al., 2014).
Conclusion
A constitutional deficit in verbal intelligence and fluency, signifi-
cantly exceeding – at a group level – the levels manifest in the
general population of patients with psychoses, is a phenotypic
indicator of TR psychosis. Our findings are in keeping with emer-
ging evidence that TR psychosis is a pathogenically distinct and
severe variant, embedded in aberrant neurodevelopmental
processes.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291718002957.
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